TITLE: C1 Esterase Inhibitor for the Treatment of Hereditary Angioedema: Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines

DATE: 15 June 2012

RESEARCH QUESTIONS

1. What is the clinical effectiveness of C1 esterase inhibitor for the treatment of hereditary angioedema?

2. What is the clinical evidence on the safety of C1 esterase inhibitor for the treatment of hereditary angioedema?

3. What is the cost-effectiveness of C1 esterase inhibitor for the treatment of hereditary angioedema?

4. What are the evidence-based guidelines for the use of C1 esterase inhibitor for the treatment of hereditary angioedema?

KEY MESSAGE

Seven studies were identified regarding the clinical effectiveness and safety of C1 esterase inhibitor for the treatment of hereditary angioedema. No guidelines or information regarding the cost-effectiveness of the treatment were identified.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2012, Issue 5), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and abbreviated lists of major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2007 and June 8, 2012. Internet links were provided, where available.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, economic evaluations, and evidence-based guidelines.

One meta-analysis, three randomized controlled trials, and three non-randomized studies were identified regarding the clinical effectiveness and safety of C1 esterase inhibitor for the treatment of hereditary angioedema. No relevant health technology assessments, systematic reviews, economic analyses, or evidence-based guidelines were identified. Additional references of potential interest are provided in the appendix.

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses


Randomized Controlled Trials


Non-Randomized Studies


**Economic Evaluations**
No literature identified.

**Guidelines and Recommendations**
No literature identified.

**PREPARED BY:**
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
[www.cadth.ca](http://www.cadth.ca)
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies

No comparator group


Home versus physician administration


Guidelines, Recommendations, and Consensus (rigour of methodology unknown)


Review Articles


